Despite factors that include a current population of people who are obese and do not exercise or eat as healthy as recommended, Michael Weber, MD, explains that the epidemiology of cardiometabolic conditions has improved due to the developments of more tolerable, effective pharmaceutical agents.
Dr Weber continues by discussing how there has been a decline in cardiovascular events thanks to these agents, which most notably have improved the outlook on hypertension and lipid disorders.
However, when assessing which cardiometabolic conditions have improved the most, Dr Weber concludes that diabetes is lagging behind and determines that more effective treatments for diabetes are necessary.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More